Advertisement Athenagen commences Alzheimer's trial - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Athenagen commences Alzheimer’s trial

Athenagen has commenced a phase II study of the its lead compound, GTS-21, in patients with Alzheimer's disease.

GTS-21 has demonstrated memory and cognition enhancement activity in human clinical trials. GTS-21 has been studied in multiple phase I studies in healthy volunteers and one phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated.

In a phase I study in healthy adults, GTS-21 also demonstrated cognitive enhancement across all doses, with a statistically significant improvement in attention and memory tasks.

“In preclinical and clinical studies, GTS-21 has shown positive benefits in the ability to improve attention, learning and memory impairment, all of which are debilitating cognitive deficiencies associated with numerous medical conditions,” said Scott Harkonen, Athenagen president and CEO.

The current phase II clinical trial is a dose-ranging study designed to evaluate both safety and cognitive effects in patients with early Alzheimer's disease. Athenagen expects to complete this trial in the second quarter of 2007.